Latest Articles
Medicus Pharma gets UAE approval for Phase 2a p... - Pluang
Medicus Pharma gets UAE approval for Phase 2a p... Pluang
Published: July 31, 2026, 12:04 p.m.
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix - Quiver Quantitative
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix Quiver Quantitative
Published: July 31, 2026, 11:40 a.m.
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix - quiverquant.com
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix quiverquant.com
Published: July 31, 2026, 11:40 a.m.
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer - Endpoints News
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Published: July 31, 2026, 10:42 a.m.
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix - Proactive financial news
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix Proactive financial news
Published: July 31, 2026, 9:24 a.m.
Following backlash, this lifesaving endometriosis and breast cancer drug will be free indefinitely - bodyandsoul.com.au
Following backlash, this lifesaving endometriosis and breast cancer drug will be free indefinitely bodyandsoul.com.au
Published: July 30, 2026, 11:45 p.m.
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Published: July 30, 2026, 11:38 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Published: July 30, 2026, 9:16 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - tipranks.com
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint tipranks.com
Published: July 30, 2026, 9:16 p.m.
Link copied to clipboard!